💧 GU Oncology — 2026-W39

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Large real-world cross-sectional study in Oncologist analyzing first-line treatment patterns for metastatic hormone-sensitive prostate cancer across Europe and Asia from 2020-2024. Shows an ongoing shift from ADT monotherapy toward combination doublet/triplet regimens, informing benchmarking of guideline-concordant care adoption.

Retrospective cohort study of metastatic prostate cancer patients combining Lu-PSMA-617 with metastasis-directed radiotherapy, published in Radiotherapy and Oncology. Suggests focal radiation can be safely integrated with radioligand therapy without compromising tolerability or efficacy, informing sequencing strategies pending prospective confirmation.

Exploratory reconstructed individual-patient-data benchmarking analysis using TALAPRO-2 trial data in HRR-deficient metastatic castration-resistant prostate cancer, published in Japanese Journal of Clinical Oncology. Descriptive, non-randomized comparisons suggest talazoparib plus enzalutamide may narrow the prognostic gap for HRR-deficient disease, but authors caution these findings do not establish equivalence or superiority.

Retrospective multi-institutional cohort study in high-risk clear cell RCC patients eligible for adjuvant pembrolizumab, published in European Urology Oncology. Finds early initiation of adjuvant pembrolizumab was not independently associated with disease-free survival overall, but risk-stratified analyses suggest greater absolute benefit in higher-risk subgroups, informing patient selection nuances.

Preclinical mechanistic study using cell lines, xenografts, and sequencing datasets, published in Clin Transl Med, showing TMEM59L drives neuroendocrine differentiation and enzalutamide resistance in prostate cancer. Identifies a potential therapeutic target but lacks patient-outcome validation, limiting immediate clinical impact.

Perspective/review in European Urology discussing pitfalls in interpreting circulating tumor DNA (tumor fraction, clonal hematopoiesis, variant pathogenicity) in advanced prostate cancer. Offers guidance for avoiding misinterpretation of ctDNA results when making treatment decisions, but is conceptual rather than a new clinical dataset.

Pilot case report/series in Frontiers in Oncology identifying nectin-4 expression in squamous cell carcinoma of the prostate, a rare androgen-deprivation-refractory subtype. Suggests nectin-4-targeted therapy (e.g., enfortumab vedotin) as a potential future option, though no clinical outcome data with such therapy are provided.

Retrospective biomarker study in localized upper tract urothelial carcinoma, published in European Urology Oncology, evaluating urine and plasma tumor DNA as a molecular staging tool. Suggests ctDNA/utDNA testing could improve selection of patients for neoadjuvant chemotherapy beyond standard imaging and biopsy, but needs prospective validation.

Retrospective genomic/transcriptomic cohort study in metastatic hormone-sensitive prostate cancer, published in The Oncologist. Identifies exploratory gene alterations (e.g., ZMYM3, JAK1) associated with failure to achieve deep PSA response, but findings are largely hypothesis-generating and not yet actionable.

Preclinical CRISPR/Cas9 screening study in Oncogene identifying the BIRC6-AS1/BIRC6 axis as a mediator of abiraterone resistance in prostate cancer via DNA repair and A20 degradation. Mechanistic findings with in vitro/in vivo validation but no patient-derived clinical outcome data, limiting immediate clinical applicability.

Preclinical study in Cancer Research identifying BUB1B/CENP-E as a mitotic kinase dependency driving castration- and enzalutamide-resistant prostate cancer, using cell line and in vivo models. Suggests CENP-E inhibition as a potential new therapeutic target, but no clinical/patient data yet to guide treatment decisions.

Retrospective secondary analysis of a randomized trial (ENABLE study) in castration-resistant prostate cancer patients on enzalutamide or abiraterone, published in International Journal of Clinical Oncology. Finds diabetes/hypertension in smokers is associated with worse prostate cancer-specific survival, particularly with enzalutamide, offering a nuance for treatment selection in this subgroup.

ASTRO clinical practice guideline in Practice Radiation Oncology (Q2) providing consensus recommendations on radiation therapy indications and technique for bladder cancer across localized, node-positive, postoperative, and metastatic settings, including its integration with systemic therapy in trimodal bladder-preservation approaches. Primarily radiation-oncology focused but informs multidisciplinary decision-making relevant to systemic therapy sequencing.

Case report in Semin Oncol describing severe rhabdomyolysis from a pharmacokinetic interaction between abiraterone and rosuvastatin in a metastatic castration-resistant prostate cancer patient, linked to a pharmacogenetic variant. Highlights an actionable drug-drug interaction risk for oncologists co-prescribing statins with abiraterone.